Myocardial depression by IL-6 is reversed by P38 MAP kinase inhibition

被引：0
|
作者：
Franklin, JL
Pathan, N
Levin, M
Harding, SE
机构：
[1] Univ London Imperial Coll Sci & Technol, NHLI, London, England
[2] Univ London Imperial Coll Sci & Technol, Acad Pediat, London, England
来源：
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY | 2005年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
064
引用
收藏
页码：1021 / 1021
页数：1
相关论文
共 50 条
  • [31] The development p38 MAP kinase inhibitors
    Hynes, John
    Wu, H.
    Dyckman, A. J.
    Lin, S.
    Wrobleski, S. T.
    Gillooly, K. M.
    McIntyre, K. W.
    Pitt, S.
    Shen, D. R.
    Shuster, D. J.
    Xia, X.
    Zhang, R.
    INFLAMMATION RESEARCH, 2007, 56 : S474 - S474
  • [32] HSP90 inhibitors potentiate PGF2α-induced IL-6 synthesis via p38 MAP kinase in osteoblasts
    Fujita, Kazuhiko
    Tokuda, Haruhiko
    Kuroyanagi, Gen
    Yamamoto, Naohiro
    Kainuma, Shingo
    Kawabata, Tetsu
    Sakai, Go
    Nishiwaki, Rie
    Otsuka, Takanobu
    Kozawa, Osamu
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2017, 133 (03) : S197 - S197
  • [33] Inhibitors of unactivated p38 MAP kinase
    Bullington, James
    Argentieri, Dennis
    Averill, Kristin
    Carter, Demetrius
    Cavender, Druie
    Fahmy, Bohumila
    Fan, Xiaodong
    Hall, Daniel
    Heintzelman, Geoffrey
    Jackson, Paul
    Leung, Wai-Ping
    Li, Xun
    Ling, Ping
    Olini, Gilbert
    Razler, Thomas
    Reuman, Michael
    Rupert, Kenneth
    Russell, Ronald
    Siekierka, John
    Wadsworth, Scott
    Wolff, Russell
    Xiang, Bangping
    Zhang, Yue-Mei
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (23) : 6102 - 6106
  • [34] Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease
    Marie Fisk
    Parag R. Gajendragadkar
    Kaisa M. Mäki-Petäjä
    Ian B. Wilkinson
    Joseph Cheriyan
    American Journal of Cardiovascular Drugs, 2014, 14 : 155 - 165
  • [35] INHIBITION OF p38 MAP KINASE BY UTILIZING A NOVEL ALLOSTERIC BINDING SITE
    Tong, L.
    Pargellis, C.
    Churchill, L.
    Cirillo, P.
    Gilmore, T.
    Graham, A. G.
    Grob, P. M.
    Hickey, E. R.
    Moss, N.
    Pav, S.
    Regan, J.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2002, 58 : C231 - C231
  • [36] Ischemic preconditioning or p38 MAP kinase inhibition attenuates myocardial TNF α production and mitochondria damage in brief myocardial ischemia
    Kimura, H
    Shintani-Ishida, K
    Nakajima, M
    Liu, S
    Matsumoto, K
    Yoshida, K
    LIFE SCIENCES, 2006, 78 (17) : 1901 - 1910
  • [37] Continued exploration of the triazolopyridine scaffold as a platform for p38 MAP kinase inhibition
    Jerome, Kevin D.
    Rucker, Paul V.
    Xing, Li
    Shieh, Huey S.
    Baldus, John E.
    Selness, Shaun R.
    Letavic, Michael A.
    Braganza, John F.
    McClure, Kim F.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (02) : 469 - 473
  • [38] Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation
    Kuliopulos, A
    Mohanlal, R
    Covic, L
    THROMBOSIS AND HAEMOSTASIS, 2004, 92 (06) : 1387 - 1393
  • [39] Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease
    Fisk, Marie
    Gajendragadkar, Parag R.
    Maeki-Petaejae, Kaisa M.
    Wilkinson, Ian B.
    Cheriyan, Joseph
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2014, 14 (03) : 155 - 165
  • [40] Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
    Pargellis, C
    Tong, L
    Churchill, L
    Cirillo, PF
    Gilmore, T
    Graham, AG
    Grob, PM
    Hickey, ER
    Moss, N
    Pav, S
    Regan, J
    NATURE STRUCTURAL BIOLOGY, 2002, 9 (04) : 268 - 272
12345